Luke Evnin Sells 58,980 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $0.57, for a total value of $33,618.60. Following the transaction, the director directly owned 2,309,869 shares in the company, valued at approximately $1,316,625.33. This trade represents a 2.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total transaction of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total transaction of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $22,448.16.

Werewolf Therapeutics Trading Down 0.6%

Shares of HOWL stock opened at $0.57 on Wednesday. The company has a market capitalization of $27.74 million, a P/E ratio of -0.35 and a beta of 0.77. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The business’s 50 day moving average is $0.87 and its two-hundred day moving average is $1.24. Werewolf Therapeutics, Inc. has a twelve month low of $0.53 and a twelve month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. Equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of HOWL. Jane Street Group LLC purchased a new position in Werewolf Therapeutics in the 2nd quarter valued at approximately $409,000. Citadel Advisors LLC acquired a new stake in Werewolf Therapeutics in the third quarter valued at $304,000. Vanguard Group Inc. increased its position in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Werewolf Therapeutics during the 2nd quarter worth $113,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Werewolf Therapeutics during the 2nd quarter worth $92,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on HOWL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Bank of America dropped their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Citizens Jmp cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. HC Wainwright decreased their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 19th. Finally, Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective on the stock. in a report on Friday, December 19th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.